Clinical trial
Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer…
NCT00338039 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00338039 |
|---|---|
| Title | Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients |
| Official title | Induction Cetuximab (IM-C225), Gemcitabine and Oxaliplatin, Followed by Radiotherapy With Concurrent Capecitabine, and Cetuximab, Followed by Maintenance Cetuximab and Gemcitabine for Patients With Locally Advanced Pancreatic Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug, Radiation |
| Interventions | Cetuximab, Gemcitabine, Oxaliplatin, Capecitabine, Radiotherapy |
| Enrollment | 69 |
| Start date | Sep 1, 2005 |
| Primary completion | Jun 1, 2011 |
| Completion | Jun 1, 2011 |
| First posted | Jun 20, 2006 |
| Last update posted | Mar 22, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: